Home › Trial NCT03591731
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
- Trial IDNCT03591731
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorIntergroupe Francophone de Cancerologie Thoracique
- Enrollment185
- Start date2019-01-02
- ConditionsNeuroendocrine Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.